News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Around 7% of the Indian population suffers from IBS
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
The workshop was conducted as a part of the NITI–State workshop series
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
Phase 3 data expected in the second half of 2024
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Subscribe To Our Newsletter & Stay Updated
